Latest Kaiser Health News Stories
KHN’s Sarah Jane Tribble discusses the twists and turns with CBS News.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Rebecca Adams of CQ Roll Call, Kimberly Leonard of the Washington Examiner and Alice Ollstein of Politico discuss how the Democrats’ takeover of the House and other results from the Nov. 6 elections might affect health care, and what Congress may have in store for the lame-duck session.
For mothers in recovery from opioid addiction, narcotic pain relief during and after delivery can put sobriety at risk.
And new study finds no reason to get routine vitamin D tests, researchers say.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Rebecca Adams of CQ Roll Call and Joanne Kenen of Politico discuss the Trump administration’s new birth control coverage rules and the potential impact of the midterm election results on health policy.
Democrats, who have a history of championing the Affordable Care Act and railing about drug prices, will now chair several house committees.
Critics worry the marketing of Vascepa, a purified fish oil product, could prove a fish story.
Medical treatments targeting the DNA in tumor cells are celebrated, but insurers often won’t cover the skyrocketing cost.
Over the past five months, the Trump administration has proposed a series of reforms to lower the cost of prescription drugs.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Anna Edney of Bloomberg News, Kimberly Leonard of the Washington Examiner and Alice Ollstein of Politico discuss a flurry of proposals from the Trump administration on prices Medicare pays for drugs and the Affordable Care Act.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Rebecca Adams of CQ Roll Call, Stephanie Armour of The Wall Street Journal and Joanne Kenen of Politico discuss how protections for people with preexisting conditions have become a top issue in the elections, Trump administration efforts to make prescription drug prices more public and the start of Medicare’s annual open-enrollment period. Plus, Rovner interviews California Attorney General Xavier Becerra.
Drugmakers’ contributions to lawmakers have peaked as surging drug prices emerge as a hot-button political issue. In the past decade, Congress has received nearly $79 million from 68 pharma PACs, run by employees of companies that make drugs treating everything from cancer to erectile dysfunction.
A new Kaiser Health News database tracks campaign donations from drugmakers over the past 10 years.
Drug pricing is a top issue in the run-up to the midterm elections.
In this episode of KHN’s “What the Health?” Mary Agnes Carey of Kaiser Health News, Rebecca Adams of CQ Roll Call, Anna Edney of Bloomberg News and Julie Appleby of Kaiser Health News discuss the Trump administration’s announcement that average premium prices are falling on the Obamacare marketplaces, the effort by Senate Democrats to reverse rules on short-term health insurance and the focus on protections for people with preexisting conditions in the run-up to midterm elections.
Congress approved two bills last month that prohibit provisions keeping pharmacists from telling patients when they can save money by paying the cash price instead of the price negotiated by their insurance plan.